Menopausal hormone therapy has played an important part in women’s health care for decades, for millions of women. These women and the regulating agencies are very sensitive to possible adverse effects. Therefore, it is necessary to assure the validity of hormone therapy pharmacovigilance.

Jeremy Hunt, UK health secretary, has assertively announced plans to impose consultant contracts that dictate consultant presence in hospitals 24 h a day, 7 days a week (24/7).1 The Royal College of Obstetricians and Gynaecologists, in its report High Quality Women’s Health Care: A Proposal for Change, has also recommended 168 h of consultant presence per week in maternity units with more than 6000 births per year.2

In 2004, the United Nations Population Fund (UNFPA) and its partners launched the Campaign to End Fistula, yet how much has changed for women’s health since its conception? Overall, improvements in women’s health would appear positive; as maternal and child mortality rates have halved in the past two decades, a successful foundation has been established for the Sustainable Development Goals (SDG).1 This is a remarkable achievement for many developing countries in view of the rise in population size, declining rates in income growth, and increasing political instability.